Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

02-08-2016

Mapping painDETECT, a neuropathic pain screening tool, to the EuroQol (EQ-5D-3L)

Auteurs: Joseph C. Cappelleri, Vijaya Koduru, E. Jay Bienen, Alesia Sadosky

Gepubliceerd in: Quality of Life Research | Uitgave 2/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To map relationships between painDETECT, a neuropathic pain (NeP) screening tool, and EQ-5D-3L health status in a real-world setting.

Methods

Patients with physician-confirmed NeP and painDETECT score classifications of nociceptive (n = 79), transitional (n = 141), and NeP (n = 386) completed the EuroQol (EQ-5D-3L), which evaluates Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression with three ordinal response levels (“no problem,” “some problems,” or “extreme problems/unable to do”), and has a health status thermometer (0 = worst health, 100 = perfect health). Multiple linear and logistic regressions were performed (adjusted for age, gender, race, ethnicity, time since NeP diagnosis, number of comorbidities, NeP conditions).

Results

Unadjusted mean (±SD) EQ-5D-3L thermometer scores showed poorer health status across painDETECT classifications from nociceptive (67.3 ± 22.1) to transitional (62.3 ± 20.9) to NeP (53.7 ± 21.8), as did utility scores, 0.695 ± 0.206, 0.615 ± 0.216, and 0.506 ± 0.216. In general, the highest odds of health problems were observed for NeP and the lowest for nociceptive, e.g., the NeP group was 6.2 (95 % confidence interval 3.4–11.4) times as likely to have a more severe problem of Usual Activities compared with the nociceptive group. Relative to nociceptive and transitional, NeP had lower adjusted mean thermometer scores, by 12.1 (P < 0.0001) and 7.8 (P = 0.0004) points, respectively, and lower mean utility scores by 0.157 (P < 0.0001) and 0.092 points (P < 0.0001).

Conclusions

This study, the first to map relationships between painDETECT and the EQ-5D-3L in a real-world setting, indicates that the patient burden with respect to pain classification can be characterized and quantified by decrements in health status overall and in specific domains. These data support the psychometric soundness of painDETECT, enhancing its use in pain management.
vorige artikel Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients’ preferences
volgende artikel Reducing respondent burden: validation of the Brief Impact of Vision Impairment questionnaire
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
2.
van Hecke, O., Austin, S. K., Khan, R. A., Smith, B. H., & Torrance, N. (2014). Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain, 155(4), 654–662.CrossRefPubMed
3.
McDermott, A. M., Toelle, T. R., Rowbotham, D. J., Schaefer, C. P., & Dukes, E. M. (2006). The burden of neuropathic pain: results from a cross-sectional survey. European Journal of Pain, 10(2), 127–135.CrossRefPubMed
4.
Attal, N., Lanteri-Minet, M., Laurent, B., Fermanian, J., & Bouhassira, D. (2011). The specific disease burden of neuropathic pain: Results of a French nationwide survey. Pain, 152(12), 2836–2843.CrossRefPubMed
5.
Langley, P. C., Van Litsenburg, C., Cappelleri, J. C., & Carroll, D. (2013). The burden associated with neuropathic pain in Western Europe. Journal of Medical Economics, 16(1), 85–95.CrossRefPubMed
6.
Schaefer, C., Mann, R., Sadosky, A., Daniel, S., Parsons, B., Nieshoff, E., et al. (2014). Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: A patient-centered evaluation. Pain Medicine, 15(12), 2105–2119.CrossRefPubMedPubMedCentral
7.
Attal, N., Cruccu, G., Baron, R., Haanpaa, M., Hansson, P., Jensen, T. S., et al. (2010). EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology, 17(9), 1113–1123.CrossRefPubMed
8.
Dworkin, R. H., O’Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpaa, M. L., et al. (2010). Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clinic Proceedings, 85(3 Suppl), S3–14.CrossRefPubMedPubMedCentral
9.
Bouhassira, D., Attal, N., Alchaar, H., Boureau, F., Brochet, B., Bruxelle, J., et al. (2005). Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 114(1–2), 29–36.CrossRefPubMed
10.
Bennett, M. I., Attal, N., Backonja, M. M., Baron, R., Bouhassira, D., Freynhagen, R., et al. (2007). Using screening tools to identify neuropathic pain. Pain, 127(3), 199–203.CrossRefPubMed
11.
Freynhagen, R., Baron, R., Gockel, U., & Tolle, T. R. (2006). painDETECT: A new screening questionnaire to identify neuropathic components in patients with back pain. Current Medical Research and Opinion, 22(10), 1911–1920.CrossRefPubMed
12.
Cappelleri, J. C., Bienen, E. J., Koduru, V., & Sadosky, A. (2014). Measurement properties of painDETECT by average pain severity. ClinicoEconomics and Outcomes Research, 6, 497–504.PubMedPubMedCentral
13.
The EuroQol Group. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
14.
Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: An online database. Health Quality of Life Outcomes, 11, 151.CrossRefPubMedPubMedCentral
15.
Torrance, N., Lawson, K. D., Afolabi, E., Bennett, M. I., Serpell, M. G., Dunn, K. M., et al. (2014). Estimating the burden of disease in chronic pain with and without neuropathic characteristics: Does the choice between the EQ-5D and SF-6D matter? Pain, 155(10), 1996–2004.CrossRefPubMedPubMedCentral
16.
Gu, N. Y., Bell, C., Botteman, M. F., Ji, X., Carter, J. A., & van Hout, B. (2012). Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. Patient, 5(3), 185–197.PubMed
17.
Baron, R., Tölle, T. R., Gockel, U., Brosz, M., & Freynhagen, R. (2009). A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain, 146(1–2), 34–40.CrossRefPubMed
18.
Baron, R., Forster, M., & Binder, A. (2012). Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: A first step to a stratified treatment approach. Lancet Neurology, 11(11), 999–1005.CrossRefPubMed
19.
Freeman, R., Baron, R., Bouhassira, D., Cabrera, J., & Emir, B. (2014). Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain, 155(2), 367–376.CrossRefPubMed
20.
Bouhassira, D., Wilhelm, S., Schacht, A., Perrot, S., Kosek, E., Cruccu, G., et al. (2014). Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study. Pain, 155(10), 2171–2179.CrossRefPubMed
21.
Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.CrossRefPubMed
22.
Sadosky, A., Schaefer, C., Mann, R., Bergstrom, F., Baik, R., Parsons, B., et al. (2013). Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: Results from a retrospective chart review and cross-sectional survey. Diabetes Metabolic Syndrome Obesity, 5, 1–14.CrossRef
23.
Mann, R., Bergstrom, F., Schaefer, C., Sadosky, A., Zlateva, G., Baik, R., et al. (2012). Characteristics of subjects with human immunodeficiency virus-related neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study. Presented at: American Society of Regional Anesthesia and Pain Medicine 11th Annual Pain Medicine Meeting, Miami, FL, 15–18 November.
24.
Parsons, B., Schaefer, C., Mann, R., Sadosky, A., Daniel, S., Nalamachu, S., et al. (2013). Economic and humanistic burden of post-trauma and post-surgical neuropathic pain among adults in the United States. Journal of Pain Research, 6, 459–469.PubMedPubMedCentral
25.
Mann, R., Bergstrom, F., Schaefer, C., Sadosky, A., Daniel, S., Parsons, B., et al. (2013). Burden of spinal cord injury-related neuropathic pain in the United States: Retrospective chart review and cross-sectional survey. Spinal Cord, 51(7), 564–570.CrossRefPubMed
26.
Sadosky, A., Schaefer, C., Parsons, B., Baik, R., Mann, R., Bergstrom, F., et al. (2012). Characteristics of subjects with chronic low back pain-related neuropathic pain (CLBP-NeP) in the US: BEAT Neuropathic pain observational study [abstract]. Annals of Neurology, 72(Suppl), 117.
27.
Schaefer, C., Mann, R., Sadosky, A., Daniel, S., Parsons, B., Nalamachu, S., et al. (2014). Health status, function, productivity, and costs among individuals with idiopathic painful peripheral neuropathy with small fiber involvement in the United States: Results from a retrospective chart review and cross-sectional survey. Journal of Medical Economics, 17(6), 394–407.CrossRefPubMed
28.
Szende, A., Devlin, N., & Oppe, M. (2006). EQ-5D value sets: inventory, comparative review and user guide (p. 108). New York: EuroQol Group Monographs, Springer.
29.
Sullivan, P. W., Ghushchyan, V., Wyatt, H. R., Wu, E. Q., & Hill, J. O. (2007). Impact of cardiometabolic risk factor clusters on health-related quality of life in the US. Obesity (Silver Spring), 15(2), 511–521.CrossRef
30.
Cleeland, C. S., & Ryan, K. M. (1994). Pain assessment: global use of the brief pain inventory. Annals of the Academy of Medicine, Singapore, 23(2), 129–138.PubMed
31.
Kleinbaum, D. G., & Klein, M. (2010). Logistic regression. A self-learning text (3rd ed.). New York: Springer.CrossRef
32.
Kleinbaum, D. G., Kupper, L. L., Nizam, A., & Rosenberg, E. S. (2014). Applied regression analysis and other multivariate methods (5th ed.). Boston: Cengage Learning.
33.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale: Lawrence Erlbaum Associates.
34.
Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality Life Outcomes, 5, 70.CrossRef
35.
Coteur, G., Feagan, B., Keininger, D. L., & Kosinski, M. (2009). Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease. Alimentary Pharmacology and Therapeutics, 29(9), 1032–1041.CrossRefPubMed
36.
Zanini, A., Aiello, M., Adamo, D., Casale, S., Cherubino, F., Della Patrona, S., et al. (2015). Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respiratory Care, 60(1), 88–95.CrossRefPubMed
37.
Szende, A., & Janssen, B. (2014). Population norms for the EQ-5D. In J. M. Cabases, A. Szende, & B. Janssen (Eds.), Self-reported population health: An international perspective based on EQ-5D (pp. 19–30). Berlin: Springer.CrossRef
38.
Sullivan, P. W., Lawrence, W. F., & Ghushchyan, V. (2005). A national catalog of preference-based scores for chronic conditions in the United States. Medical Care, 43(7), 736–749.CrossRefPubMed
39.
Cappelleri, J. C., Koduru, V., Bienen, E. J., & Sadosky, A. (2015). A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic pain. Journal of Pain Research, 8, 159–167.PubMedPubMedCentral
40.
Ananth, C. V., & Kleinbaum, D. G. (1997). Regression models for ordinal responses: A review of methods and applications. International Journal of Epidemiology, 26(6), 1323–1333.CrossRefPubMed
41.
Gu, N. Y., Botteman, M. F., Ji, X., Bell, C. F., Carter, J. A., & van Hout, B. (2011). Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities. Health and Quality of Life Outcomes, 9, 119.CrossRefPubMedPubMedCentral
42.
Sidovar, M. F., Limone, B. L., Lee, S., & Coleman, C. I. (2013). Mapping the 12-item multiple sclerosis walking scale to the EuroQol 5-dimension index measure in North American multiple sclerosis patients. BMJ Open. doi:10.​1136/​bmjopen-2013-002798.
43.
Khan, K. A., Madan, J., Petrou, S., & Lamb, S. E. (2014). Mapping between the Roland Morris Questionnaire and generic preference-based measures. Value in Health, 17(6), 686–695.CrossRefPubMed
Metagegevens
Titel
Mapping painDETECT, a neuropathic pain screening tool, to the EuroQol (EQ-5D-3L)
Auteurs
Joseph C. Cappelleri
Vijaya Koduru
E. Jay Bienen
Alesia Sadosky
Publicatiedatum
02-08-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 2/2017
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1379-2

Andere artikelen Uitgave 2/2017

Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

  • Open Access

Quality of life of pediatric oncology patients: Do patient-reported outcome instruments measure what matters to patients?

The role of flexible goal adjustment in the effect of informal caregiving on depressive symptoms: Evidence of a large population-based longitudinal study in Germany from 2002 to 2011

Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients’ preferences

Depression risk in patients with late-onset rheumatoid arthritis in Germany

The impact of patient-reported outcome measures in clinical practice for pain: a systematic review

  • Open Access
  • Review